Cullinan Therapeutics's net tangible assets is $370M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Cullinan Therapeutics (CGEM) currently reports a net tangible assets of $370M as of March 2026. That compares with $550M in the prior-year period — down 33.6% year over year. Use the charts on this page to explore Cullinan Therapeutics's net tangible assets history and peer comparisons.
Cullinan Therapeutics's net tangible assets decreased from $550M to $370M — a 33.6% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Cullinan Therapeutics reported $370M in net tangible assets as of March 2026. That compares with $550M in the prior-year period — down 33.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current net tangible assets of $370M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cullinan Therapeutics, and consider following CGEM for alerts when major investors trade the stock.
Cullinan Therapeutics is classified in the Healthcare sector. On net tangible assets, it currently shows $370M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CGEM with unrelated industries.